CR10308A - Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito - Google Patents

Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito

Info

Publication number
CR10308A
CR10308A CR10308A CR10308A CR10308A CR 10308 A CR10308 A CR 10308A CR 10308 A CR10308 A CR 10308A CR 10308 A CR10308 A CR 10308A CR 10308 A CR10308 A CR 10308A
Authority
CR
Costa Rica
Prior art keywords
growth factor
humanized monoclonal
hepatocite
monoclonal antibodies
pharmaceutical composition
Prior art date
Application number
CR10308A
Other languages
English (en)
Inventor
Jin Kim Kyung
Wang Lihong
Park Hangil
Vasquez Maximiliano
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of CR10308A publication Critical patent/CR10308A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se dirige hacia un anticuerpo monoclonal humanizado neutralizador del factor de crecimiento del hepatocito, una composicion farmaceutica que lo incluye, y los metodos de tratamiento que incluyen la adminsitracion de tal composicion farmaceutica a un paciente.
CR10308A 2006-04-01 2008-09-22 Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito CR10308A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78824306P 2006-04-01 2006-04-01

Publications (1)

Publication Number Publication Date
CR10308A true CR10308A (es) 2008-10-27

Family

ID=38564195

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10308A CR10308A (es) 2006-04-01 2008-09-22 Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito

Country Status (25)

Country Link
US (3) US7632926B2 (es)
EP (2) EP2016162B1 (es)
JP (1) JP5312315B2 (es)
KR (1) KR101516289B1 (es)
CN (2) CN103172736A (es)
AR (1) AR059922A1 (es)
AU (1) AU2007233242B2 (es)
BR (1) BRPI0709932A2 (es)
CA (1) CA2645358C (es)
CO (1) CO6140067A2 (es)
CR (1) CR10308A (es)
ES (1) ES2465668T3 (es)
GE (1) GEP20125517B (es)
IL (1) IL194221A (es)
MA (1) MA30382B1 (es)
MX (1) MX2008012619A (es)
MY (1) MY145042A (es)
NO (1) NO20084539L (es)
NZ (1) NZ571132A (es)
PE (1) PE20080008A1 (es)
RU (1) RU2461570C2 (es)
TW (1) TWI417300B (es)
UA (1) UA94452C2 (es)
WO (1) WO2007115049A2 (es)
ZA (1) ZA200807903B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
NZ544797A (en) 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
KR20080026562A (ko) * 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
JP4560582B2 (ja) 2006-06-02 2010-10-13 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
WO2007145840A2 (en) * 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AU2008209482B2 (en) 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
MX2010009669A (es) * 2008-03-06 2010-09-22 Genentech Inc Terapia de combinacion con antagonistas de c-met y egfr.
EP2636513B1 (en) * 2008-04-10 2014-08-27 Stratasys Ltd. System and method for three dimensional model printing
CL2009000844A1 (es) * 2008-04-11 2009-06-12 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es agonista de pten.
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
WO2009126840A1 (en) * 2008-04-11 2009-10-15 Galaxy Biotech, Llc Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
AU2009246263B2 (en) * 2008-05-14 2014-08-21 Amgen Inc. Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer
BRPI0912035A2 (pt) 2008-05-29 2017-05-23 Galaxy Biotech Llc anticorpo monoclonal, composição farmacêutica, uso de uma composição farmacêutica, mab de camundongo na forma quimérica ou humanizada, e, anticorpo humanizado
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CA2729602A1 (en) 2008-07-08 2010-01-14 Oncomed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
PL3290052T3 (pl) 2008-11-07 2020-06-29 Galaxy Biotech, Llc Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
EP2360183B1 (en) 2008-12-19 2016-07-27 Takeda Pharmaceutical Company Limited Antibody purification method by mixed mode chromatography utilizing an arginine-containing loading solution
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
US20120177651A1 (en) * 2009-05-28 2012-07-12 Neil James Clarke Antigen-binding proteins
WO2011088215A2 (en) * 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2011110642A2 (en) 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
CN103391773A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
SG190362A1 (en) * 2010-11-24 2013-06-28 Glaxo Group Ltd Multispecific antigen binding proteins targeting hgf
US20140234328A1 (en) 2011-09-09 2014-08-21 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
KR20150140685A (ko) * 2013-03-14 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 Hgf에 대한 항체 및 이를 포함하는 조성물
US9732150B2 (en) 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
US10941204B2 (en) 2015-10-30 2021-03-09 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4
KR20250065434A (ko) 2016-03-01 2025-05-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
US20220275368A1 (en) 2019-08-12 2022-09-01 Interna Technologies B.V. New treatments involving mirna-193a
EP4041392A1 (en) 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
CN115461461A (zh) 2020-02-28 2022-12-09 因特尔纳技术有限公司 用于促进免疫原性细胞死亡的miRNA-193a
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CN119285785B (zh) * 2024-09-26 2025-04-18 武汉奥科博泰生物科技有限公司 一种抗d-二聚体单克隆抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2000515735A (ja) 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
WO2000069915A2 (en) * 1999-05-17 2000-11-23 Avi Biopharma, Inc. COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES
AU1598801A (en) 1999-11-09 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The HGF-SF monoclonal antibody combinations
EP1423432A4 (en) 2001-07-26 2006-01-11 Lilly Co Eli ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
EP1516185A4 (en) 2001-12-27 2007-06-20 Van Andel Res Inst Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
WO2004019991A2 (en) 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
AU2003900180A0 (en) * 2003-01-16 2003-01-30 Silverbrook Research Pty Ltd Method and apparatus (dam001)
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EP2093570A1 (en) 2003-06-06 2009-08-26 Genentech, Inc. Modulating the interaction between HGF beta chain and c-met
CA2539190A1 (en) 2003-07-07 2005-01-27 George F. Vande Woude Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
NZ544797A (en) 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
KR20060079227A (ko) 2003-09-18 2006-07-05 코닌클리케 필립스 일렉트로닉스 엔.브이. 정보매체와, 그 정보매체에 저장된 데이터 판독 시스템
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
US7708991B2 (en) * 2004-02-17 2010-05-04 Stc.Unm Method for treating cancer and identifying novel anti-cancer compounds
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
KR20080026562A (ko) 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
US7964365B2 (en) 2005-11-08 2011-06-21 The United States of Americam as represented by the Secretary, Department of Health and Human Services Methods for diagnosing and monitoring the progression of cancer
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
CN101415811B (zh) 2013-01-30
KR20090013777A (ko) 2009-02-05
ZA200807903B (en) 2010-03-31
US20080019974A1 (en) 2008-01-24
CA2645358C (en) 2015-05-05
RU2008143318A (ru) 2010-05-10
HK1121489A1 (en) 2009-04-24
TWI417300B (zh) 2013-12-01
ES2465668T3 (es) 2014-06-06
CO6140067A2 (es) 2010-03-19
NO20084539L (no) 2008-10-28
MX2008012619A (es) 2008-10-13
KR101516289B1 (ko) 2015-05-07
AU2007233242B2 (en) 2012-04-26
UA94452C2 (ru) 2011-05-10
MY145042A (en) 2011-12-15
EP2476704A2 (en) 2012-07-18
JP2009532378A (ja) 2009-09-10
AR059922A1 (es) 2008-05-07
US20140335076A1 (en) 2014-11-13
EP2476704A3 (en) 2012-07-25
RU2461570C2 (ru) 2012-09-20
TW200808828A (en) 2008-02-16
BRPI0709932A2 (pt) 2011-08-02
JP5312315B2 (ja) 2013-10-09
US7632926B2 (en) 2009-12-15
EP2016162B1 (en) 2014-04-16
US8628778B2 (en) 2014-01-14
IL194221A (en) 2015-11-30
CN101415811A (zh) 2009-04-22
WO2007115049A3 (en) 2008-09-04
AU2007233242A1 (en) 2007-10-11
WO2007115049A2 (en) 2007-10-11
PE20080008A1 (es) 2008-02-14
NZ571132A (en) 2012-05-25
GEP20125517B (en) 2012-05-25
CA2645358A1 (en) 2007-10-11
MA30382B1 (fr) 2009-05-04
EP2016162A4 (en) 2009-11-11
US20100278815A1 (en) 2010-11-04
EP2016162A2 (en) 2009-01-21
CN103172736A (zh) 2013-06-26

Similar Documents

Publication Publication Date Title
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CL2020000263A1 (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco.
CL2007002404A1 (es) Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
DOP2017000177A (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
CO6382188A2 (es) Anticuerpos monoclonales que se unen al hgm-csf y composiciones medicas que los comprenden
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
CL2016002585A1 (es) Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373)
CR20160319A (es) Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
PE20100251A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
MX2016013704A (es) Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer.
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
MX340295B (es) Anticuerpos monoclonales anti-c-met.
CR20120577A (es) Anticuerpos hacia gdf8 humano
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2018000135A (es) Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).
EA201100884A1 (ru) Моноклональные антитела анти-rhd
MX349235B (es) Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs).
MX2020003034A (es) Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)